KD 025, CAS 911417-87-3

Shelf life (days): 1460.0

Formulation: A crystalline solid

Formal Name: 2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)-acetamide

Purity: ≥98%

Formula Markup: C26H24N6O2

Formula Weight: 452.5

CAS Number: 911417-87-3

Notes: KD 025 is an inhibitor of Rho-associated kinase 2 (ROCK2; IC50 = 0.105 µM).{28734} It is selective for ROCK2 over ROCK1 (IC50 = 24 µM). KD 025 (10 µM) decreases the expression of connective tissue growth factor (CTGF) and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells. It inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 1.25 to 10 µM.{58833} KD 025 (100 and 200 mg/kg) reduces infarct volume in a mouse model of cerebral ischemia induced by transient middle cerebral artery occlusion (MCAO).{28726} It decreases disease severity in a mouse model of sclerodermatous chronic graft versus host disease (GVHD) when administered at a dose of 150 mg/kg.{58834} Formulations containing KD 025 have been used in the treatment of chronic GVHD.

• Artikelnummer: CAY17055-100
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 17055-100
• Verpackungseinheit: 100 mg
• Mengeneinheit: STK